The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice

Gu, Yue; Avolio, Elisa; Alvino, Valeria V; Thomas, Anita C; Herman, Andrew; Miller, Poppy J; Sullivan, Niall; Faulkner, Ashton; Madeddu, Paolo

doi:10.1186/s12933-023-01955-9

Authors

Yue Gu

Elisa Avolio

Valeria V Alvino

Anita C Thomas

Andrew Herman

Poppy J Miller

Niall Sullivan

Ashton Faulkner

Paolo Madeddu

Citation

Gu, Y., Avolio, E., Alvino, V. V., Thomas, A. C., Herman, A., Miller, P. J., …Madeddu, P. (in press). The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice. Cardiovascular Diabetology, 22(1), https://doi.org/10.1186/s12933-023-01955-9

Journal Article Type	Article
Acceptance Date	Aug 8, 2023
Online Publication Date	Aug 17, 2023
Deposit Date	Aug 21, 2023
Publicly Available Date	Aug 23, 2023
Journal	Cardiovascular Diabetology
Publisher	BioMed Central
Peer Reviewed	Peer Reviewed
Volume	22
Issue	1
DOI	https://doi.org/10.1186/s12933-023-01955-9
Keywords	Cardiology and Cardiovascular Medicine; Endocrinology, Diabetes and Metabolism
Additional Information	Received: 5 June 2023; Accepted: 8 August 2023; First Online: 17 August 2023; : ; : Experimental procedures involving human patients were covered by ethical approval from Wales Rec 4 (REC reference number: 14/WA/1005) and in compliance with the “Declaration of Helsinki” principles. Patients gave written informed consent for participation in the study.; : Experimental procedures involving mice were approved by the British Home Office (PPL number PP1377882), the University of Bristol, and were compliant with the EU Directive 2010/63/EU and principles stated in the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, 1996).; : Not Applicable.; : The authors declare no competing interests.